Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02786485 | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | withdrawn | Phase 1 | 0 | Bellicum PharmaceuticalsINDUSTRY | 0 | Oct 5, 2020 | clinicaltrials |
| NCT03888534 | Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) | withdrawn | Phase 1 | 0 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 28, 2020 | clinicaltrials |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 28, 2020 | clinicaltrials |
| NCT01460602 | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Louisiana State University Health Sciences Center ShreveportOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT04355039 | INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 0 | Aug 19, 2020 | clinicaltrials |
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT04233697 | Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma | withdrawn | Phase 1 | 0 | Columbia UniversityOTHER | 0 | Aug 13, 2020 | clinicaltrials |
| NCT00004114 | Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 31, 2020 | clinicaltrials |
| NCT03506802 | TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma(NYSCT MM) | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02547948 | CD19-targeting CAR T Cells for B Cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT04106076 | Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Cellectis S.A.INDUSTRY | 0 | Jul 14, 2020 | clinicaltrials |
| NCT04013880 | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Jul 7, 2020 | clinicaltrials |
| NCT02923986 | Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS | withdrawn | Phase 1 / Phase 2 | 0 | Bio-Path Holdings, Inc.INDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT03617224 | Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome | withdrawn | Phase 1 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Apr 22, 2020 | clinicaltrials |
| NCT03986086 | MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation | withdrawn | Phase 1 / Phase 2 | 0 | Nelson ChaoOTHER | 1 | Mar 20, 2020 | clinicaltrials |
| NCT04043845 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Feb 5, 2020 | clinicaltrials |
| NCT02800889 | Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer | withdrawn | Phase 1 | 0 | CTI BioPharmaINDUSTRY | 1 | Jan 29, 2020 | clinicaltrials |
| NCT03579927 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 29, 2020 | clinicaltrials |
| NCT01789723 | Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn | withdrawn | Phase 1 | 0 | Acrotech Biopharma Inc.INDUSTRY | 0 | Jan 23, 2020 | clinicaltrials |
| NCT02274506 | Infusion of Allogeneic, 3rd Party CD19-specific T Cells | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 22, 2020 | clinicaltrials |
| NCT03760445 | HDM201 Added to CT in R/R or Newly Diagnosed AML | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jan 9, 2020 | clinicaltrials |
| NCT01415765 | MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 17, 2019 | clinicaltrials |
| NCT00085449 | Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT03612739 | EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2(EPITHINK) | withdrawn | Phase 1 | 0 | Celyad Oncology SAINDUSTRY | 0 | Oct 29, 2019 | clinicaltrials |
| NCT02709993 | Consolidation Therapy in Patients With Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Kiromic BioPharma Inc.INDUSTRY | 1 | Oct 14, 2019 | clinicaltrials |
| NCT02729961 | Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | University of WashingtonOTHER | 1 | Oct 10, 2019 | clinicaltrials |
| NCT03575078 | ARQ761 + PARP Inhibitor in Refractory Solid Tumors | withdrawn | Phase 1 | 0 | University of Texas Southwestern Medical CenterOTHER | 0 | Sep 25, 2019 | clinicaltrials |
| NCT02053545 | Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion | withdrawn | Phase 1 / Phase 2 | 0 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Aug 30, 2019 | clinicaltrials |
| NCT02871323 | Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT03657420 | Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | Massachusetts General HospitalOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT03752138 | TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 6, 2019 | clinicaltrials |
| NCT03373305 | Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT00829647 | A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Scripps HealthOTHER | 0 | Apr 11, 2019 | clinicaltrials |
| NCT02826642 | A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 10, 2019 | clinicaltrials |
| NCT03856112 | Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Mar 26, 2019 | clinicaltrials |
| NCT03705858 | Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Joseph JurcicOTHER | 0 | Mar 8, 2019 | clinicaltrials |
| NCT03699384 | Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) | withdrawn | Phase 1 / Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT02611908 | Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. | withdrawn | Phase 1 | 0 | Michael ChoiOTHER | 0 | Jan 25, 2019 | clinicaltrials |
| NCT02657447 | Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02) | withdrawn | Phase 1 | 0 | Nordic NanovectorINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT02378922 | Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 27, 2018 | clinicaltrials |
| NCT03591744 | Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03349346 | Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents | withdrawn | Phase 1 | 0 | Gilead SciencesINDUSTRY | 4 | Dec 11, 2018 | clinicaltrials |
| NCT03531281 | Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT02343666 | HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT02228512 | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Aug 31, 2018 | clinicaltrials |
| NCT02223312 | Therapy for Progressive and/or Refractory Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Kiromic BioPharma Inc.INDUSTRY | 0 | Aug 28, 2018 | clinicaltrials |
| NCT02545361 | Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Kahr MedicalINDUSTRY | 0 | Aug 16, 2018 | clinicaltrials |
| NCT01751243 | Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies | withdrawn | Phase 1 | 0 | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y SaludOTHER | 1 | Jul 6, 2018 | clinicaltrials |
| NCT02472626 | 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT02905994 | Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Massachusetts General HospitalOTHER | 1 | May 4, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Oct 5, 2020source: clinicaltrials